U.S. Markets closed

NGM Biopharmaceuticals, Inc. (NGM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.59+0.03 (+0.54%)
At close: 04:00PM EST
5.46 -0.13 (-2.33%)
After hours: 07:57PM EST

NGM Biopharmaceuticals, Inc.

333 Oyster Point Boulevard
South San Francisco, CA 94080
United States
650 243 5555

Full Time Employees225

Key Executives

NameTitlePayExercisedYear Born
Mr. William J. Rieflin J.D.Exec. Chairman of DirectorsN/AN/A1960
Dr. David J. Woodhouse Ph.D.CEO & Director880.75k356.19k1971
Ms. Siobhan Nolan ManginiPres, Principal Financial, Accounting Officer & CFO of NGM Biopharmaceuticals610.75kN/A1981
Dr. Jin-Long Chen Ph.D.Founder, Chief Scientific Officer & Director730.75k6.28M1963
Ms. Valerie L. Pierce J.D.Sr. VP, Gen. Counsel, Sec. & Chief Compliance Officer582.75kN/A1963
Dr. Hsiao Dee LieuChief Medical Officer & Sr. VP625.75k111.4k1970
Brian SchoelkopfSr. Director of Corp. Fin. & IRN/AN/AN/A
Mr. Brian MumaVP of People OperationsN/AN/AN/A
Dr. Alex DePaoliChief Translational Officer & Sr. VPN/AN/AN/A
Jessica Ferreyra Ph.D.Chief of Staff, ResearchN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck & Co., Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

Corporate Governance

NGM Biopharmaceuticals, Inc.’s ISS Governance QualityScore as of October 1, 2022 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 9; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.